开云app官网登录入口网页版-官方正版

#CD13#

13篇内容 | 990人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1928018, encodeId=038a19280186f, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=肿瘤免疫明星靶点：靶向CD137的双抗策略, objectType=article, longId=726917, objectId=8018e269177f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8018e269177f, replyNumber=0, likeNumber=86, createdTime=2023-01-01, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8018e269177f, moduleTitle=肿瘤免疫明星靶点：靶向CD137的双抗策略, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8018e269177f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928017, encodeId=6613192801e0c, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Nature Communications：PD-1/CD137双抗效果优异，安全性良好, objectType=article, longId=220377, objectId=c40c2203e71e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c40c2203e71e, replyNumber=0, likeNumber=82, createdTime=2022-07-01, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c40c2203e71e, moduleTitle=Nature Communications：PD-1/CD137双抗效果优异，安全性良好, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c40c2203e71e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928016, encodeId=5c2e192801650, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果, objectType=article, longId=212351, objectId=4525212351b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4525212351b7, replyNumber=0, likeNumber=100, createdTime=2022-04-03, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4525212351b7, moduleTitle=礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4525212351b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928014, encodeId=9e531928014dc, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, objectType=article, longId=185937, objectId=58ff18593e64, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58ff18593e64, replyNumber=0, likeNumber=76, createdTime=2020-11-23, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58ff18593e64, moduleTitle=Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=58ff18593e64)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928015, encodeId=dafb1928015ef, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Int J Pharm：CD13特异性配体能够促进苍儿素纳米药物靶向树突细胞来治疗难治性过敏性鼻炎, objectType=article, longId=187666, objectId=60c818e6662e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60c818e6662e, replyNumber=0, likeNumber=66, createdTime=2020-10-24, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60c818e6662e, moduleTitle=Int J Pharm：CD13特异性配体能够促进苍儿素纳米药物靶向树突细胞来治疗难治性过敏性鼻炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=60c818e6662e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928012, encodeId=67c51928012b7, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Pediatr Allergy Immunol：过敏源特异性免疫疗法能够改善CD8+ CD25+ CD137+调节T细胞和减少鼻一氧化氮, objectType=article, longId=165248, objectId=d2f816524853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2f816524853, replyNumber=0, likeNumber=73, createdTime=2020-03-18, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2f816524853, moduleTitle=Pediatr Allergy Immunol：过敏源特异性免疫疗法能够改善CD8+ CD25+ CD137+调节T细胞和减少鼻一氧化氮, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d2f816524853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928013, encodeId=bf1f192801366, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Blood：CD137缺陷是一种新型先天性免疫缺陷，与早发型淋巴瘤相关, objectType=article, longId=179256, objectId=e0431e9256e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0431e9256e4, replyNumber=0, likeNumber=65, createdTime=2019-10-02, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0431e9256e4, moduleTitle=Blood：CD137缺陷是一种新型先天性免疫缺陷，与早发型淋巴瘤相关, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e0431e9256e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928011, encodeId=2ab9192801140, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=INT J LAB HEMATOL：对286个成熟B细胞肿瘤的整合流式细胞术分析显示，CD13可作为诊断亚型的有用标记, objectType=article, longId=159375, objectId=c0fc1593e543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0fc1593e543, replyNumber=0, likeNumber=69, createdTime=2019-10-09, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0fc1593e543, moduleTitle=INT J LAB HEMATOL：对286个成熟B细胞肿瘤的整合流式细胞术分析显示，CD13可作为诊断亚型的有用标记, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c0fc1593e543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928010, encodeId=670319280108e, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Blood：GATA6过表达可诱导CD137配体异常表达，进而促进皮肤T细胞淋巴瘤进展, objectType=article, longId=148521, objectId=7ce6148521ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ce6148521ff, replyNumber=0, likeNumber=73, createdTime=2019-03-08, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ce6148521ff, moduleTitle=Blood：GATA6过表达可诱导CD137配体异常表达，进而促进皮肤T细胞淋巴瘤进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7ce6148521ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928009, encodeId=009c1928009c2, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Sci Rep：通过抑制CD133的表达miRNA-142-3p增加人脐带血单核细胞的放射敏感性, objectType=article, longId=135331, objectId=5a5113533104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a5113533104, replyNumber=0, likeNumber=66, createdTime=2018-12-04, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a5113533104, moduleTitle=Sci Rep：通过抑制CD133的表达miRNA-142-3p增加人脐带血单核细胞的放射敏感性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5a5113533104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928008, encodeId=bcfe192800880, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Stemcells：EIF5A2可通过c-Myc/miR-29b轴维持CD133+的肝癌细胞的存活, objectType=article, longId=121439, objectId=8712121439b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8712121439b0, replyNumber=0, likeNumber=75, createdTime=2018-10-11, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8712121439b0, moduleTitle=Stemcells：EIF5A2可通过c-Myc/miR-29b轴维持CD133+的肝癌细胞的存活, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8712121439b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928007, encodeId=a4f1192800e2f, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=PloS One：CD13 表达在治疗非小细胞肺癌中的潜在作用, objectType=article, longId=102414, objectId=4a5f10241479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a5f10241479, replyNumber=0, likeNumber=76, createdTime=2018-04-13, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a5f10241479, moduleTitle=PloS One：CD13 表达在治疗非小细胞肺癌中的潜在作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4a5f10241479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1928006, encodeId=6e3e192800643, content=<a href='/topic/show?id=a6b54263ae' target=_blank style='color:#2F92EE;'>#CD13#</a>, objectTitle=Virchows Arch：CD133在区分乳管内乳头状侵袭良恶性肿瘤的诊断价值, objectType=article, longId=44052, objectId=b79f440528d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b79f440528d, replyNumber=0, likeNumber=79, createdTime=2015-04-20, rootId=0, userName=hyf028, userId=7d40148, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b79f440528d, moduleTitle=Virchows Arch：CD133在区分乳管内乳头状侵袭良恶性肿瘤的诊断价值, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b79f440528d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

CD13

2020-05-29

hyf028 (审核中...)

前往app查看评论内容

#CD13#

肿瘤免疫明星靶点：靶向CD137的双抗策略

2023-01-01

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Nature Communications：PD-1/CD137双抗效果优异，安全性良好

2022-07-01

hyf028 (审核中...)

前往app查看评论内容

#CD13#

礼进生物在2021 ASCO年会上公布其CD137/4-1BB激动剂抗体LVGN6051的1期临床研究中期结果

2022-04-03

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Bicycle Therapeutics宣布与英国癌症研究中心合作开发新型肿瘤免疫学候选药物——多价CD137激动剂BT7401

2020-11-23

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Int J Pharm：CD13特异性配体能够促进苍儿素纳米药物靶向树突细胞来治疗难治性过敏性鼻炎

2020-10-24

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Pediatr Allergy Immunol：过敏源特异性免疫疗法能够改善CD8+ CD25+ CD137+调节T细胞和减少鼻一氧化氮

2020-03-18

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Blood：CD137缺陷是一种新型先天性免疫缺陷，与早发型淋巴瘤相关

2019-10-02

hyf028 (审核中...)

前往app查看评论内容

#CD13#

INT J LAB HEMATOL：对286个成熟B细胞肿瘤的整合流式细胞术分析显示，CD13可作为诊断亚型的有用标记

2019-10-09

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Blood：GATA6过表达可诱导CD137配体异常表达，进而促进皮肤T细胞淋巴瘤进展

2019-03-08

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Sci Rep：通过抑制CD133的表达miRNA-142-3p增加人脐带血单核细胞的放射敏感性

2018-12-04

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Stemcells：EIF5A2可通过c-Myc/miR-29b轴维持CD133+的肝癌细胞的存活

2018-10-11

hyf028 (审核中...)

前往app查看评论内容

#CD13#

PloS One：CD13 表达在治疗非小细胞肺癌中的潜在作用

2018-04-13

hyf028 (审核中...)

前往app查看评论内容

#CD13#

Virchows Arch：CD133在区分乳管内乳头状侵袭良恶性肿瘤的诊断价值

2015-04-20

科室
- - 订阅+
  - 更多科室
工具
服务